BMS commits $8m in grants to fuel health equity mission

Bristol Myers Squibb (BMS) has announced the awarding of 24 health equity grants, given to non-profit organizations dedicated to improving access to and quality of care to underserved patients and communities. The pharmaceutical company reports the grants are intended to bolster outreach and education; increase patient support and care coordination; and support diversity, cultural competency, and collaboration among community health workers and patient navigators, across therapeutic areas.

To learn more about the grants and BMS’s overall commitment to increasing diversity and inclusivity, Outsourcing-Pharma connected with Adam Lenkowsky, senior vice president and general manager of US commercial with BMS; he also serves as executive sponsor of BMS’ Health Equity Initiative.

OSP: Could you please talk about some of the key achievements/events in BMS’ history of promoting greater equity in care and research?

AL: Multiple health equity efforts were underway at BMS before COVID-19. However, the pandemic exposed and further exacerbated health and healthcare inequities for underserved communities nationwide, and the deaths of members from these communities sparked a national reckoning on racism.

In 2020, BMS launched our D&I and Health Equity Commitments, a $150m, five-year investment to address health disparities, increase clinical trial diversity, expand supplier diversity, increase workforce representation and enhance employee giving in support of social justice organizations. Separately and independently, the BMS Foundation, which has a long history in health equity, also committed $150m toward health equity, clinical trial diversity, and employee giving.


Leave a Reply

Your email address will not be published.